1. Scrip
  2. >>Business

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

 
• By Kevin Grogan

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

PlatePie
Bayer wants more than just a slice of Vitrakvi pie • Source: Shutterstock

With Eli Lilly & Co. sealing the deal to acquire its partner Loxo Oncology Inc., Bayer AG has moved swiftly to take full control of its tissue-agnostic drug Vitrakvi rather than share the rights to the closely watched cancer therapy with a fellow big pharma.

The German major first teamed up with Loxo back in November 2017 and a year later the FDA approved Vitrakvi (larotrectinib) for the treatment of both adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.